RxSight, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Sales	$33,637	$34,887	$71,531	$64,399
Cost of sales	8,447	10,637	18,013	19,464
Gross profit	25,190	24,250	53,518	44,935
Operating expenses:
Selling, general and administrative	28,976	24,292	57,611	47,616
Research and development	10,217	8,291	20,584	16,322
Total operating expenses	39,193	32,583	78,195	63,938
Loss from operations	(14,003)	(8,333)	(24,677)	(19,003)
Other income (expense), net:
Interest expense	(5)	(6)	(11)	(11)
Interest and other income	2,254	2,276	4,762	3,860
Loss before income taxes	(11,754)	(6,063)	(19,926)	(15,154)
Income tax expense	32	16	50	25
Net loss	$(11,786)	$(6,079)	$(19,976)	$(15,179)
Other comprehensive loss
Unrealized loss on short-term investments	(146)	(64)	(303)	(109)
Foreign currency translation gain (loss)	14	(1)	20	(4)
Total other comprehensive loss	(132)	(65)	(283)	(113)
Comprehensive loss	$(11,918)	$(6,144)	$(20,259)	$(15,292)
Net loss per share:
Basic & diluted	$(0.29)	$(0.16)	$(0.49)	$(0.40)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic & diluted	40,743,786	38,455,955	40,627,363	37,649,521

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.